We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Aug 2021 - 26 Aug 2021
Virtual Venue
29 Aug 2021 - 31 Aug 2021
Virtual Venue

Protein Biomarker Helps Diagnose Pancreatic Cancer

By LabMedica International staff writers
Posted on 14 Jul 2021
Print article
Image: The Super Sensitive 1-STEP Polymer HRP IHC detection kit (Photo courtesy of BioGenix)
Image: The Super Sensitive 1-STEP Polymer HRP IHC detection kit (Photo courtesy of BioGenix)
Pancreatic ductal adenocarcinoma (PDAC), characterized by dense desmoplastic stroma laid down by pancreatic stellate cells (PSC), has no reliable diagnostic biomarkers for timely detection.

Most cancer biomarkers used in clinical practice are proteins released from the cancer cells themselves. One of the defining features of PDAC is that there are very few cancer cells. Pancreatic cancer is surprisingly made up of mostly non-cancer cells, which have been co-opted by cancer to build a huge amount of scar tissue or stroma around the cancer, providing a strong defense for the cancer cells.

Oncologists at the Queen Mary University of London (London, UK) and their colleagues analyzed blood samples from 267 donors including 140 samples from patients with PDAC Controls included patients with non-neoplastic pancreatico-biliary diseases as well as healthy individuals. Pentraxin 3 (PTX3) concentrations were quantified using the sandwich ELISA method. Western blotting was carried out and quantified using Fiji-ImageJ.

Other methods employed by the scientists were immunofluorescence, immunohistochemical analysis of human tissues (Super Sensitive IHC kit, BioGenix, Houston, TX, USA); mRNA in situ hybridization (ISH) was measured with RNAscope 2.5 HD duplex reagent assay (Advanced Cell Diagnostics, Newark, CA, USA); mini-organotypics; small interfering RNA studies; MTS assay for cell viability. Quantification of all cell counts and intensity of staining was performed in at least three representative images per mini-organotypic gel, and representative images per gel were acquired using a confocal laser scanning microscope LSM 880 (Carl Zeiss, White Plains, NY, USA).

The investigators reported that serum PTX3 above 4.34 ng/mL has a higher sensitivity (86%, 95% confidence interval (CI): 65–97%) and specificity (86%, 95% CI: 79–91%), positive predictive value (97%) and likelihood ratio (6.05), and is superior when compared to serum CA19-9 and CEA for detection of PDAC. The team found that when pancreatic cancer alone is targeted, PTX3 does not seem to change upon administration of chemotherapy; however, when medications targeting both cancer and stroma are administered, changes are seen in PTX3 levels. This change in PTX3 can be easily measured in blood to monitor how the drug is working. Thus, PTX3 may help in monitoring the effectiveness of treatment much earlier than scans may be able to indicate treatment response.

The authors concluded that their study suggests that PTX3 may be a sensitive and specific biomarker able to distinguish cancerous from non-cancerous conditions of the pancreas. The team hopes the findings will provide direction for future prospective clinical trials to determine whether PTX3 could be effective in the clinic as a biomarker for early detection and, perhaps, used in conjunction with other biomarkers to monitor response to treatment of pancreatic cancer. The study was published on June 29, 2021 in the journal npj Precision Oncology.


Related Links:
Queen Mary University of London
BioGenix
Advanced Cell Diagnostics
Carl Zeiss


New
Gold Supplier
Microplate Washer
MW-12A
New
Gold Supplier
Proficiency Assessment Software
CellaVision Proficiency Software
New
L.pneumophila Assay
Uni-Gold Legionella Urinary Antigen PLUS
New
SARS-CoV-2 NGS Test
Illumina COVIDSeq Test

Print article

Channels

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.